Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00813098 · ClinicalTrials.gov registry record · Phase 2
Study of LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome
A Phase 2 study, sponsored by Lexicon Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 155
- Enrollment target
NCT00813098 is a Phase 2 study that has completed, run by Lexicon Pharmaceuticals. The registered enrollment target is 155 participants.
The verdict
NCT00813098, a Phase 2 study, has completed, sponsored by Lexicon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 155 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety, tolerability, and effectiveness of LX1031 versus a placebo control in subjects with non-constipating irritable bowel syndrome.
Interventions
- DRUG Placebo
- DRUG LX1031 High Dose
- DRUG LX1031 Low Dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2008-12 |
| Est. Completion | 2010-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00813098
The ClinicalTrials.gov registry entry for NCT00813098 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 155 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lexicon Pharmaceuticals, which has 56 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00813098 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00813098 about?
NCT00813098 is a clinical study titled "Study of LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome". The purpose of the study is to evaluate the safety, tolerability, and effectiveness of LX1031 versus a placebo control in subjects with non-constipating irritable bowel syndrome.
What is the current status of trial NCT00813098?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 155 participants. The study started on 2008-12. Estimated completion is 2010-08.
What interventions are being tested in trial NCT00813098?
The interventions under investigation include: Placebo (DRUG), LX1031 High Dose (DRUG), LX1031 Low Dose (DRUG).
Who is sponsoring clinical trial NCT00813098?
This trial is sponsored by Lexicon Pharmaceuticals, which has 56 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.